Cargando…

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF

Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative col...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romero-Cara, Patricia, Torres-Moreno, Daniel, Pedregosa, José, Vílchez, Juan Antonio, García-Simón, María Sergia, Ruiz-Merino, Guadalupe, Morán-Sanchez, Senador, Conesa-Zamora, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765734/ https://www.ncbi.nlm.nih.gov/pubmed/29333082 http://dx.doi.org/10.7150/ijms.22812

Ejemplares similares

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis
por: Avila-Pedretti, Gabriela, et al.
Publicado: (2015)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis
por: Morgan, Ann W, et al.
Publicado: (2006)

Polymorphism of FCGR3A gene in chronic beryllium disease
por: Liu, Bing, et al.
Publicado: (2018)

Comparative Analysis of FCGR Gene Polymorphism in Pulmonary Sarcoidosis and Tuberculosis
por: Typiak, Marlena, et al.
Publicado: (2023)

Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
por: Márquez Pete, Noelia, et al.
Publicado: (2021)

Single Nucleotide Polymorphism rs10919543 in FCGR2A/FCGR3A Region Confers Susceptibility to Takayasu Arteritis in Chinese Population
por: Qin, Fang, et al.
Publicado: (2016)

Protective effects of FCGR2A polymorphism in invasive pneumococcal diseases
por: Bouglé, A, et al.
Publicado: (2012)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

FCGR2B and FCRLB Gene Polymorphisms Associated with IgA Nephropathy
por: Zhou, Xu-jie, et al.
Publicado: (2013)

Association of FCGR3A and FCGR3B haplotypes with rheumatoid arthritis and primary Sjögren's syndrome
por: Mackie, S, et al.
Publicado: (2005)

FCGR2A and FCGR3A Genotypes in Human Immunodeficiency Virus Mother-to-Child Transmission
por: Milligan, Caitlin, et al.
Publicado: (2015)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014)

Association of FCGR2A/FCGR3A variant rs2099684 with Takayasu arteritis in the Han Chinese population
por: Chen, Si, et al.
Publicado: (2016)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Male-specific association of the FCGR2A His167Arg polymorphism with Kawasaki disease
por: Kwon, Young-Chang, et al.
Publicado: (2017)

FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant
por: Paul, Pascale, et al.
Publicado: (2019)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

FCGR Genetic Variation in Two Populations From Ecuador Highlands—Extensive Copy-Number Variation, Distinctive Distribution of Functional Polymorphisms, and a Novel, Locally Common, Chimeric FCGR3B/A (CD16B/A) Gene
por: Moraru, Manuela, et al.
Publicado: (2021)

Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer
por: Sáenz-López, Pablo, et al.
Publicado: (2008)

Downregulated APOD and FCGR2A correlates with immune infiltration and lipid-induced symptoms of irritable bowel syndrome
por: Ran, Yamei, et al.
Publicado: (2023)

Association of FCGR3A and FCGR3B Copy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients
por: Chen, Ji-Yih, et al.
Publicado: (2014)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis
por: Zhang, Chang'e, et al.
Publicado: (2016)

The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients
por: López-Martínez, Rocío, et al.
Publicado: (2022)

Copy number variation of FCGR genes in etiopathogenesis of sarcoidosis
por: Typiak, Marlena, et al.
Publicado: (2017)

Messenger RNA of FCGR3A and FCGR3B Genes as Monitoring Markers of Clear Cell Renal Adenocarcinoma (a Pilot Study)
por: Alyasova, A.V., et al.
Publicado: (2022)

Monitoring of anti-TNF biological treatments
por: Ruiz del Agua, A, et al.
Publicado: (2010)

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
por: Salvador-Martín, Sara, et al.
Publicado: (2023)

BALB/c-Fcgr2b(−/−)Pdcd1(−/−) mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis
por: Sugino, Yoshio, et al.
Publicado: (2012)

TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ujfnkup8tqhbv8hbu6ral7ofln